{
  "id": "antibiotic",
  "title": "Antibiotic",
  "lang": "en",
  "source_lang": "en",
  "summary": "An antibiotic is a substance that kills bacteria or inhibits their growth, used chiefly to treat or prevent bacterial infections.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "Antibacterial drug",
    "antibacterial agent"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/antibiotic/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/antibiotic/",
      "json": "https://aiwiki.page/zh/antibiotic.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "An antibiotic is a substance that kills bacteria or inhibits their growth and is used chiefly to treat or prevent bacterial infections. Historically, the term referred to antimicrobial substances produced by microorganisms; in modern medical usage, it commonly includes semisynthetic derivatives and fully synthetic antibacterial drugs. Antibiotics do not treat viral infections such as influenza or the common cold, although they may be used when a bacterial infection occurs alongside a viral illness.\n\nAntibiotics transformed medicine during the twentieth century by making many previously lethal infections treatable. They also helped make complex surgery, intensive cancer treatment, and organ transplantation practicable by reducing the risks associated with bacterial infection. Their effectiveness depends on selective action against bacterial structures or processes, adequate exposure at the infected site, and susceptibility of the organism responsible.\n\nThe same biological processes that make antibiotics useful also create limits to their use. Bacteria can possess or acquire resistance, treatment can disrupt beneficial microbial communities, and individual drugs can cause serious adverse effects. Antibiotics therefore connect molecular biology and pharmacology with clinical diagnosis, industrial production, agriculture, and public health."
    },
    {
      "heading": "Definition, scope, and classification",
      "text": "The boundaries of the term antibiotic have changed since its introduction. Its strict historical meaning distinguishes naturally produced microbial substances from synthetic antibacterial agents such as sulfonamides. Contemporary clinical language usually groups both together because their therapeutic purposes and many of their practical problems are similar. The broader term antimicrobial also includes antifungal, antiparasitic, and antiviral drugs. An antiseptic, by contrast, is applied to living tissue to reduce microorganisms locally; disinfectants are used on objects and surfaces. These categories are defined partly by use and tolerability rather than by an absolute chemical boundary.\n\nAntibiotics can be classified by chemical structure, molecular target, spectrum of activity, or biological effect. Structural families include beta-lactams, aminoglycosides, tetracyclines, macrolides, glycopeptides, and fluoroquinolones. Members of one family commonly share a basic molecular framework and target, but modifications can substantially change absorption, tissue penetration, bacterial coverage, and vulnerability to resistance mechanisms. Amoxicillin and antistaphylococcal penicillins, for example, belong to the same broad family but differ in their activity against particular bacteria.\n\nThe distinction between bactericidal and bacteriostatic action describes whether a drug kills bacteria or mainly suppresses their multiplication under specified laboratory conditions. Beta-lactams and aminoglycosides are generally described as bactericidal; tetracyclines and many macrolides are commonly described as bacteriostatic. The distinction is not absolute. A drug’s behavior can change with the bacterial species, concentration, growth phase, and experimental method. Clinical success cannot be inferred from this label alone, because host defenses, infection site, and achievable exposure also matter.\n\nSpectrum describes the range of organisms against which a drug has useful activity. Narrow-spectrum agents act against a relatively restricted group, whereas broad-spectrum agents cover a wider range. These are comparative rather than precisely standardized categories. A broad-spectrum drug does not necessarily cover all bacteria associated with a particular infection, and activity against one resistant organism does not imply broad coverage of others. Drugs active against aerobic Gram-negative organisms may lack activity against anaerobes, and some agents active against Gram-positive bacteria have essentially no useful activity against Gram-negative species.\n\nClassification also distinguishes natural products, semisynthetic agents, and fully synthetic molecules. Natural products are obtained from organisms or their biosynthetic machinery; semisynthetic drugs are made by chemically modifying such products. Fully synthetic drugs are assembled through chemical synthesis. These origins do not determine clinical value: each route has produced important treatments, and each can generate compounds with substantial limitations."
    },
    {
      "heading": "Discovery and historical development",
      "text": "The antibiotic era emerged from several converging developments: the germ theory of disease, laboratory cultivation of microorganisms, chemical synthesis, and the search for substances selectively toxic to pathogens. In 1909, Paul Ehrlich and Sahachiro Hata identified the activity of the arsenical compound later marketed as Salvarsan against syphilis. Although not an antibiotic in the original natural-product sense, it helped establish the principle that a chemical could attack an infectious agent more strongly than its host.\n\nIn 1928, Alexander Fleming observed that a contaminating Penicillium mold inhibited the growth of staphylococci on a culture plate. His 1929 report described the antibacterial substance he called penicillin. Turning this observation into a practical medicine required purification, experimental testing, and manufacturing methods developed by a wider group, notably Howard Florey, Ernst Boris Chain, Norman Heatley, and their collaborators at Oxford. Systemic treatment began in the early 1940s, and industrial-scale production expanded rapidly during World War II. Fleming, Chain, and Florey shared the 1945 Nobel Prize in Physiology or Medicine.\n\nSynthetic antibacterial treatment developed alongside penicillin. Gerhard Domagk’s work on Prontosil in the early 1930s established the value of sulfonamides, whose antibacterial activity depends on sulfanilamide produced from the parent compound. These drugs demonstrated that effective antibacterial treatment need not originate in a microbial fermentation. Their introduction preceded widespread penicillin availability and provided important treatments for several systemic infections.\n\nSystematic screening of soil microorganisms then produced a succession of major discoveries. Streptomycin was isolated in 1943 by Albert Schatz in Selman Waksman’s laboratory, with Elizabeth Bugie contributing to the published work. It became an important early treatment for tuberculosis, although resistance rapidly showed the limitations of single-drug therapy. Chloramphenicol, tetracyclines, macrolides, and glycopeptides followed during the mid-twentieth century. Many originated from actinomycetes, especially members of the genus Streptomyces.\n\nFrom the 1960s onward, much progress came through modifying established chemical families. Semisynthetic penicillins, successive generations of cephalosporins, and later fluoroquinolones broadened treatment options. Resistance nevertheless appeared repeatedly, sometimes soon after introduction. The history is therefore not a simple sequence of infections permanently conquered: discovery, clinical adoption, resistance, and renewed development have repeatedly reshaped one another. It also illustrates the importance of manufacturing and distribution, because a useful laboratory compound becomes a transformative medicine only when it can be produced reliably and made available at scale."
    },
    {
      "heading": "Molecular targets and selective toxicity",
      "text": "Antibiotic activity depends on differences between bacterial and human biology. Some targets, such as peptidoglycan, are absent from human cells. Others, such as the machinery for protein synthesis, are present in both but differ enough to permit selective inhibition. Selectivity is relative rather than complete: human tissues can still be affected directly, and harm can also arise through changes to resident microorganisms.\n\nCell-wall inhibitors interfere with the structure that protects many bacteria against osmotic rupture. Beta-lactams bind penicillin-binding proteins, including enzymes responsible for cross-linking peptidoglycan. In susceptible, actively growing organisms, this disrupts wall construction and can lead to cell lysis. Glycopeptides such as vancomycin instead bind terminal peptide structures in cell-wall precursors, obstructing their incorporation into the wall. Because human cells lack peptidoglycan, these pathways provide particularly useful selective targets. Bacteria without a conventional cell wall, including Mycoplasma, are intrinsically unaffected by drugs whose activity depends on that structure.\n\nSeveral major families inhibit the bacterial ribosome. Bacterial ribosomes contain 30S and 50S subunits, which differ from the corresponding machinery in human cytoplasm. Aminoglycosides act on the 30S subunit and can induce errors in decoding genetic information. Tetracyclines impede the entry of aminoacyl-transfer RNA into the ribosome. Macrolides, including azithromycin, interact with the 50S subunit and interfere with elongation of the growing protein chain. Oxazolidinones inhibit formation of a functional initiation complex. These mechanisms explain shared features within drug families, but differences in binding and cellular entry produce distinct antibacterial spectra.\n\nOther antibiotics disrupt nucleic-acid synthesis or essential metabolic pathways. Fluoroquinolones stabilize complexes of bacterial DNA with DNA gyrase or topoisomerase IV, interfering with chromosome replication and segregation. Rifamycins inhibit bacterial RNA polymerase and thereby transcription. Sulfonamides and trimethoprim inhibit different steps in folate metabolism; their combined action can block sequential stages of the same pathway. Human cells obtain folate from external sources rather than synthesizing it through the bacterial pathway, which contributes to selectivity.\n\nMembrane-active antibiotics exploit differences in membrane composition and organization. Polymyxins interact with the outer membrane of Gram-negative bacteria and disrupt membrane integrity, but their potential toxicity restricts their clinical use. Daptomycin acts at the membrane of susceptible Gram-positive organisms in a calcium-dependent process. Its antibacterial activity is inhibited by pulmonary surfactant, illustrating why a molecularly potent drug may be unsuitable at a particular anatomical site. Across all these mechanisms, activity requires the compound to reach its target in sufficient concentration and remain there long enough to affect the organism."
    },
    {
      "heading": "Antibacterial spectrum and laboratory susceptibility",
      "text": "The distinction between Gram-positive and Gram-negative bacteria provides a useful starting point for understanding antibiotic activity. It reflects differences in cell-envelope architecture detected by Gram staining. Gram-positive bacteria generally have a thick peptidoglycan layer, whereas Gram-negative bacteria have an additional outer membrane containing lipopolysaccharide. That outer membrane restricts entry of many compounds. Porin channels permit some molecules to pass, but differences in their number, structure, and regulation can substantially alter susceptibility.\n\nSpecies identification alone does not reliably establish which antibiotics will work. Strains within one species can differ in resistance genes, target mutations, and drug-inactivating enzymes. Antimicrobial susceptibility testing therefore examines the response of a bacterial isolate to specific agents. Common methods include broth dilution, agar dilution, disk diffusion, and gradient diffusion. Automated laboratory systems can combine identification and susceptibility measurements, while molecular tests can rapidly detect selected resistance determinants.\n\nA central measurement is the minimum inhibitory concentration, or MIC: the lowest tested concentration that prevents visible growth under standardized conditions. The MIC is not a direct measurement of bacterial killing, nor is it an exact universal threshold independent of the test method. Disk diffusion instead measures the diameter of a growth-inhibition zone around an antibiotic-containing disk. Interpretation requires method-specific standards, controlled inoculum size, suitable media, incubation conditions, and quality-control organisms.\n\nLaboratory results are interpreted using clinical breakpoints established by organizations such as the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing. Breakpoints integrate MIC distributions, achievable drug exposure, pharmacological relationships, and clinical evidence. They can differ by organism, drug, dose assumptions, and sometimes infection site. Terminology also differs between systems: EUCAST’s “I” category means “susceptible, increased exposure,” rather than simply an uncertain midpoint between susceptible and resistant. Breakpoints may change as evidence and resistance patterns evolve.\n\nSusceptibility results describe a standardized laboratory system, not the whole infection. Bacteria growing in a biofilm, within an abscess, or in a poorly perfused tissue compartment may respond differently from free-growing organisms in broth. Slow growth, low oxygen availability, altered acidity, and a high bacterial burden can reduce activity. Conversely, the immune system and removal of infected material can contribute substantially to clearance. Molecular detection of a resistance gene can be highly informative, but failure to detect a limited panel does not establish susceptibility to every drug. Clinical interpretation therefore combines organism identification, laboratory results, anatomical context, and the patient’s physiological condition."
    },
    {
      "heading": "Pharmacokinetics, pharmacodynamics, and tissue exposure",
      "text": "An antibiotic must achieve an appropriate exposure at the site of infection without causing unacceptable toxicity. Pharmacokinetics describes absorption, distribution, metabolism, and elimination; pharmacodynamics describes the relationship between drug exposure and biological effect. Together, these disciplines explain why drugs with similar laboratory activity can behave differently in patients and why a susceptibility result cannot be interpreted independently of the exposure associated with a treatment regimen.\n\nAbsorption varies widely. Some antibiotics have high oral bioavailability, allowing oral administration to produce systemic exposure approaching that of intravenous administration. Others are poorly absorbed or degraded in the gastrointestinal tract. Oral vancomycin, for example, acts primarily within the intestinal lumen rather than providing reliable systemic treatment. Food, gastric conditions, and binding to metal ions can alter absorption. Tetracyclines and fluoroquinolones can form complexes with polyvalent cations, reducing the fraction available for absorption.\n\nDistribution depends on molecular size, lipid solubility, electrical charge, protein binding, blood flow, and biological barriers. The unbound fraction is generally the portion available for distribution and antibacterial action. Entry into the central nervous system is constrained by the blood–brain barrier and related interfaces; meningeal inflammation can change penetration. Drug concentrations in blood do not necessarily represent concentrations in bone, pulmonary secretions, intracellular compartments, or an abscess. Critical illness can further alter distribution through fluid shifts, capillary leakage, and changes in organ function.\n\nThree exposure indices are commonly used in antibacterial pharmacology: the proportion of time that free-drug concentration exceeds the MIC, the peak concentration relative to the MIC, and total exposure relative to the MIC. The last is often expressed as\n\n\\[\\frac{f\\mathrm{AUC}_{24}}{\\mathrm{MIC}},\\]\n\nwhere \\(f\\mathrm{AUC}_{24}\\) is the area under the unbound concentration–time curve over 24 hours. Beta-lactam activity is generally associated with time above the MIC; aminoglycoside activity is strongly concentration dependent; and exposure-to-MIC relationships are important for agents including fluoroquinolones and vancomycin. Exact targets vary by drug, organism, infection, and measured outcome.\n\nElimination commonly occurs through the kidneys, the liver, or both. Reduced kidney function can prolong exposure to renally cleared drugs, whereas augmented renal clearance in some critically ill patients can lower exposure unexpectedly. Hemodialysis and other extracorporeal treatments can remove some antibiotics. Therapeutic drug monitoring measures concentrations to help characterize exposure for selected agents, particularly when pharmacokinetic variability or toxicity is important. These measurements are interpreted alongside timing, organ function, organism susceptibility, and the clinical course rather than as isolated numbers."
    },
    {
      "heading": "Therapeutic and preventive uses",
      "text": "Antibiotics are used against bacterial infections ranging from localized skin disease to bloodstream infection and sepsis. Their clinical role depends on whether bacteria are responsible, which organisms are plausible, and whether the detected organism is causing disease rather than merely colonizing a surface. Many bacteria normally inhabit the skin, mouth, and intestine without producing illness. A positive culture is therefore not automatically evidence of an infection requiring antibacterial treatment.\n\nTreatment is often described as empirical or definitive. Empirical therapy begins before the causative organism and its susceptibility are fully established, using the infection syndrome, likely pathogens, local resistance patterns, and individual clinical factors. Definitive therapy is directed by microbiological and other diagnostic findings. Examples include treatment of pneumonia, urinary tract infection, bacterial meningitis, and infective endocarditis. Even within one syndrome, the relevant pathogens and treatment requirements differ according to age, anatomy, exposure history, immune status, and healthcare setting.\n\nAntibiotics do not replace procedures needed to control the source of infection. An abscess may require drainage; an infected device may need removal; obstructed infected urine may require relief of the obstruction. Organisms in devitalized tissue or on implanted material can be difficult to eradicate because of impaired drug delivery, persistent bacterial reservoirs, and biofilm growth. This interaction between antibacterial treatment and source control is particularly important in deep-seated infections and infections involving prosthetic material.\n\nCombination treatment serves several distinct purposes. It can broaden initial coverage when several pathogens are plausible, treat infections involving multiple organisms, produce complementary antibacterial effects, or reduce the probability that resistance will emerge during treatment. Tuberculosis is a major example of the last principle: treatment uses multiple active drugs because resistant subpopulations can be selected rapidly by inadequate single-agent exposure. Eradication of *Helicobacter pylori* also uses combination regimens. Combination therapy is not inherently superior, however; additional drugs can increase toxicity and ecological disruption without improving outcomes.\n\nPreventive use includes perioperative prophylaxis for selected procedures and prevention of particular infections in defined high-risk settings. The aim of surgical prophylaxis is to establish effective tissue concentrations during the period when contamination is likely, not to sterilize the patient indefinitely. Antibiotics also support care during neutropenia and some forms of immunosuppression, where bacterial infections can progress rapidly. The appropriate duration of either preventive or therapeutic exposure varies greatly by indication. Clinical studies have supported shorter treatment courses for several infections, while other conditions, including some bone, heart-valve, and mycobacterial infections, require substantially longer treatment."
    },
    {
      "heading": "Adverse effects and disruption of microbial communities",
      "text": "Antibiotic safety involves direct toxicity, immune-mediated reactions, interactions with other medicines, and effects on organisms other than the intended pathogen. Common adverse effects include gastrointestinal symptoms, nausea, and diarrhea, but the frequency and severity vary substantially among drugs. A reaction occurring during treatment is not necessarily caused by the antibiotic: infections themselves can cause rashes, abnormal laboratory results, and organ dysfunction. Accurate characterization is important because an imprecise adverse-reaction label can influence treatment choices for many years.\n\nAllergy represents one subset of adverse reactions. Immediate immune-mediated reactions can include urticaria, airway involvement, and anaphylaxis. Delayed reactions range from relatively mild eruptions to rare, severe syndromes affecting skin and internal organs. A recorded penicillin allergy does not always correspond to persistent, clinically significant hypersensitivity. Cross-reactivity between beta-lactams depends partly on molecular side-chain similarity rather than simply on membership in the entire beta-lactam class. Distinguishing allergy from intolerance, and distinguishing different immune mechanisms, are therefore important components of clinical assessment.\n\nDirect toxicities have characteristic associations. Aminoglycosides can injure the kidneys and the auditory or vestibular systems. Vancomycin can contribute to kidney injury and can cause infusion-related reactions that are mechanistically distinct from classic immunoglobulin E-mediated allergy. Some macrolides and fluoroquinolones can prolong cardiac repolarization, creating concern in susceptible patients or with interacting medicines. Linezolid can suppress blood-cell production during prolonged exposure and has monoamine oxidase-inhibiting activity, which underlies certain drug interactions. These are class or drug associations, not effects experienced by every recipient.\n\nAntibiotics can also disrupt the human microbiome, including organisms that contribute to colonization resistance. Suppression of protective intestinal communities can permit *Clostridioides difficile* to proliferate and produce toxins, causing disease that ranges from diarrhea to severe colitis. Altered microbial communities may also permit fungal overgrowth. The ecological effect depends on the drug’s spectrum, its concentrations within the intestine, treatment duration, and the pre-existing microbial community. Even treatment directed at an infection outside the gut can affect intestinal organisms through biliary excretion or other routes.\n\nDrug interactions can arise through altered metabolism, transport, absorption, or intestinal microbial activity. Rifampicin induces several drug-metabolizing enzymes and transport systems, reducing exposure to numerous other medicines. Some antibiotics can alter the anticoagulant effect of warfarin through several mechanisms. Safety considerations also change during pregnancy, infancy, advanced age, and impaired organ function. Pharmacovigilance continues after marketing because uncommon adverse effects, interactions, and risks in underrepresented populations may not be fully characterized in preapproval trials."
    },
    {
      "heading": "Resistance, tolerance, and bacterial evolution",
      "text": "Antibiotic resistance is the ability of bacteria to withstand drug exposures that would inhibit susceptible members of the relevant population. It is a property of microorganisms, not of the person receiving treatment. Resistance may be intrinsic to a species or acquired through genetic change. It is part of the broader problem of antimicrobial resistance, which also includes resistance in viruses, fungi, and parasites. Antibiotic exposure creates selection pressure: susceptible organisms are suppressed while organisms with advantageous resistance traits survive and reproduce.\n\nResistance mechanisms fall into several broad groups. Enzymes can destroy or modify a drug, as beta-lactamases do to susceptible beta-lactams. Changes in a target can reduce binding, exemplified by altered penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. Reduced permeability can limit entry, while efflux pumps export compounds from the cell. Some bacteria acquire alternative metabolic pathways or target-protection mechanisms. A single organism may combine several mechanisms, producing resistance across multiple drug families and narrowing the set of effective treatments.\n\nResistance can arise through mutation or through horizontal gene transfer. Plasmids, transposons, and other mobile genetic elements move resistance determinants within and between bacterial populations. Transfer can occur by conjugation, uptake of environmental DNA, or bacteriophage-mediated processes. Genes conferring resistance to several unrelated drugs may be carried together, so exposure to one agent can maintain resistance to others through co-selection. The evolutionary outcome depends on transmission, drug exposure, fitness costs, compensatory mutations, and ecological conditions.\n\nResistance differs from tolerance and persistence. Resistance generally permits growth at higher antibiotic concentrations and is often reflected by an increased MIC. Tolerance describes slower killing without necessarily changing the MIC. Persistence refers to a subpopulation that survives exposure despite lacking a stable resistance phenotype, often because of a transient physiological state. Biofilms can combine physical structure, metabolic gradients, slow-growing cells, and genetic exchange, making eradication difficult without fitting neatly into a single resistance category.\n\nThe consequences extend beyond failure of an individual prescription. Resistant organisms can spread between people, across healthcare facilities, through food production, and in environmental reservoirs. A major analysis of the 2019 global burden estimated that bacterial resistance was directly attributable to about 1.27 million deaths and associated with about 4.95 million deaths. These measures use different counterfactual comparisons and are not interchangeable. Resistance can also increase treatment complexity, toxicity, hospitalization, and reliance on costly or less accessible agents. Its distribution varies by pathogen, location, population, and healthcare setting, making local and national surveillance essential."
    },
    {
      "heading": "Stewardship, access, and the One Health perspective",
      "text": "Antimicrobial stewardship is the coordinated effort to improve antimicrobial use while preserving effective treatment. It addresses selection of agent, route, exposure, and duration, together with timely review as diagnostic information becomes available. Its purpose is not simply to reduce the volume prescribed. Inadequate access, delayed treatment, and ineffective products can cause serious harm, while unnecessary exposure creates avoidable toxicity and selection pressure. Appropriate use therefore combines restraint where antibiotics offer no benefit with reliable treatment where bacterial disease requires it.\n\nStewardship programs commonly use local treatment guidance, microbiology support, prescribing review, feedback, and restrictions on selected agents. Hospitals may review empirical therapy after early culture results, identify opportunities to narrow coverage, or assess whether intravenous treatment remains necessary. Community programs address prescribing for respiratory and other syndromes in which bacterial and nonbacterial causes can overlap. Diagnosis is central: rapid identification tests can shorten uncertainty, but a test improves outcomes only when its result is interpreted correctly and connected to treatment decisions.\n\nThe World Health Organization developed the AWaRe classification to support monitoring and stewardship. Introduced in 2017, it groups antibiotics as Access, Watch, or Reserve according to their roles and resistance-related stewardship needs. Access antibiotics include agents important for common infections with comparatively favorable resistance considerations. Watch antibiotics have greater resistance-selection concerns, while Reserve agents are intended for specific situations involving highly resistant organisms. AWaRe categories are policy tools rather than rankings of potency or universal instructions for individual cases.\n\nPrevention reduces demand for antibiotics by reducing infections themselves. Vaccination, safe water, sanitation, infection prevention in healthcare, and reliable surgical practices all contribute. Public-health surveillance links information on antibiotic consumption, bacterial susceptibility, outbreaks, and clinical outcomes. Interpretation requires attention to sampling: isolates from hospitalized patients with treatment failure can show much higher resistance than organisms circulating in the wider community. Changes in laboratory methods and testing practices can also alter apparent trends.\n\nThe One Health perspective recognizes connections among human, animal, and environmental health. Antibiotics are used in veterinary care, aquaculture, and food-animal production, and resistant organisms or genes can move among these systems. Wastewater, manure, pharmaceutical manufacturing discharges, and healthcare effluent can introduce residues and resistant organisms into the environment. Their relative contributions vary by setting and cannot be inferred from the presence of a resistance gene alone. At the same time, shortages, weak supply chains, and unaffordable medicines limit treatment in many regions. Sustainable antibiotic policy therefore involves agriculture, environmental management, manufacturing quality, and health systems, not prescribing behavior alone."
    },
    {
      "heading": "Manufacturing, discovery, and emerging approaches",
      "text": "Antibiotic production combines microbiology, chemical engineering, and pharmaceutical quality control. Many natural-product antibiotics are made by fermentation, in which a selected microbial strain grows under controlled conditions of temperature, acidity, oxygen supply, and nutrient availability. Product formation may depend on a specialized stage of growth or on tightly regulated biosynthetic pathways. Industrial strains are selected or engineered for productivity and consistency. After fermentation, the active compound must be separated from cells and other materials, purified, and formulated into a stable dosage form.\n\nSemisynthetic manufacture adds chemical or enzymatic modification to a fermentation-derived core. The development of 6-aminopenicillanic acid as a starting material enabled production of many penicillin derivatives with altered stability, absorption, and antibacterial activity. Fully synthetic agents rely instead on chemical synthesis, sometimes involving numerous steps and careful control of stereochemistry. Manufacturing quality is clinically important: incorrect active-drug content, contamination, poor stability, or unreliable dissolution can undermine exposure and safety. Sterile injectable products impose additional requirements for sterility, endotoxin control, and particulate contamination.\n\nDiscovery remains difficult because an antibacterial molecule must satisfy several constraints at once. It must reach an essential bacterial target, cross relevant permeability barriers, avoid removal by efflux, remain stable in the body, and have an acceptable safety margin. Gram-negative bacteria present especially demanding entry barriers. Screening can identify compounds that inhibit an isolated enzyme yet fail against intact bacteria because the compounds cannot enter or are rapidly exported. Conversely, whole-cell screening can reveal activity before the molecular target is known, requiring later work to establish mechanism and resistance liabilities.\n\nCurrent research includes exploration of previously difficult-to-culture microorganisms, genome mining for biosynthetic pathways, structure-guided design, and computational screening. Artificial intelligence can help prioritize candidate molecules, but predictions still require experimental confirmation, pharmacological characterization, and clinical evaluation. Beta-lactamase inhibitors illustrate another strategy: protecting an established antibiotic from bacterial enzymes rather than relying solely on a new antibacterial target. New inhibitors differ in the enzyme families they block, so their value depends on the resistance mechanism present.\n\nAlternatives and adjuncts include bacteriophages, phage-derived enzymes, anti-virulence compounds, antibodies, and approaches that modify microbial communities. Each faces distinct questions about delivery, specificity, resistance, manufacturing, and demonstration of clinical benefit. New products must ultimately be assessed in appropriately designed clinical trials, often under difficult recruitment conditions because highly resistant infections are heterogeneous and unpredictable. Economic development is also unusual: successful stewardship may appropriately limit use of a valuable new drug, while development costs remain substantial. Public funding, development partnerships, and payment models partly separated from sales volume are among the approaches used to address that mismatch."
    }
  ],
  "links": [
    "bacteria",
    "influenza",
    "common-cold",
    "medicine",
    "surgery",
    "organ-transplantation",
    "pharmacology",
    "public-health",
    "antiviral-drug",
    "antiseptic",
    "beta-lactam-antibiotic",
    "amoxicillin",
    "germ-theory-of-disease",
    "syphilis",
    "alexander-fleming",
    "penicillin",
    "world-war-ii",
    "nobel-prize-in-physiology-or-medicine",
    "tuberculosis",
    "peptidoglycan",
    "ribosome",
    "azithromycin",
    "dna",
    "antimicrobial-susceptibility-testing",
    "minimum-inhibitory-concentration",
    "biofilm",
    "immune-system",
    "pharmacokinetics",
    "pharmacodynamics",
    "central-nervous-system",
    "blood-brain-barrier",
    "kidney",
    "sepsis",
    "pneumonia",
    "urinary-tract-infection",
    "neutropenia",
    "immunosuppression",
    "nausea",
    "diarrhea",
    "allergy",
    "anaphylaxis",
    "warfarin",
    "pregnancy",
    "pharmacovigilance",
    "antibiotic-resistance",
    "antimicrobial-resistance",
    "mutation",
    "horizontal-gene-transfer",
    "diagnosis",
    "world-health-organization",
    "vaccine",
    "sanitation",
    "public-health-surveillance",
    "health-system",
    "enzyme",
    "artificial-intelligence",
    "clinical-trial"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}